20.10.2016 Rheon Medical SA, a medtech startup developing adjustable glaucoma drainage device to provide personalized control of post-operative intra-ocular pressure, has closed a financing round with BlueOcean Ventures SA as the lead investor and welcomes Thomas Zehnder on its board of directors.
Rheon Medical SA, based in the EPFL Innovation Park in Lausanne has developed adjustable glaucoma drainage device known as “eyeWatch implant”. The eyeWatch is adjustable, which gives physicians unprecedented control over the patients’ intra-ocular pressure, thereby optimising treatment and reducing complication rates.
Today, Rheon Medicals closed a financing round with BlueOcean Ventures, an investment company focused on early stage medical device and life science companies. Thomas Zehnder, General partner at BlueOcean Ventures will also be joining Rheon Medica’s board of directors. “We are delighted to join Rheon Medical as the first institutional investor,” said Zehnder,
Rheon Medical was founded by Nikos Stergiopoulos, a serial entrepreneur who has established several startups including EndoArt SA, which was sold to Allergan in 2007, and Antlia SA. “We like very much the operational experience of the BlueOcean Venture team and are pleased to welcome Thomas Zehnder in our board of directors,” said Stergiopoulos.
More about Rheon – EPFL article: http://actu.epfl.ch/news/a-micro-tap-for-treating-glaucoma/